In contrast to PDE6D knockdown and/or inhibition, forced PDE6D overexpression induced ERK activation in resistant HCC cells (Figure S1C), which might contribute to enhanced resistance to the unspecific RAF inhibitor sorafenib. This evidence concerns the gene PDE6D and hepatocellular carcinoma.